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During the past 20 years, treatments for head and neck squamous cell carcinoma (HNSCC) have changed dramatically owing largely
to the advent of novel approaches such as combined modality therapy as well as improvements in surgical and radiotherapeutic
techniques. Locally advanced disease in particular, which engendered very high recurrence and mortality rates, is now associated with
long-term disease-free survival in the majority of cases. This article will focus on locally advanced HNSCC, which frequently remains a
clinical challenge, review state-of-the-art therapy, and introduce promising novel therapies. The field continues to evolve rapidly with
new evidence during the past year clearly establishing the benefit of adjuvant chemoradiotherapy (CRT), as well as early evidence
showing improved survival with the use of an epidermal growth factor receptor inhibitor in combination with radiotherapy. There are
varied regimens in use for patients with locally advanced disease, but at the same time the multitude of options can plague the
clinician when trying to select the most appropriate one. This article will attempt to put the various approaches into perspective and
propose an evidence-based treatment algorithm.
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Head and neck cancer has an estimated annual global incidence of
533100 cases (Parkin et al, 2001) and is the fifth most common
cancer worldwide with the great majority of cases being squamous
cell carcinomas (HNSCC). There is strong geographical variance in
incidence likely related to associated risk factors, with the highest
reported rates being observed in some areas of France (Bas-Rhin,
male incidence 63.58 cases/100000 people) and India/central Asia
(Sankaranarayanan et al, 1998). The staging for HNSCC is shown
in Table 1. Treatment for locally advanced disease (stages III, IVA,
IVB), which makes up more than 50% of all cases, requires
aggressive and concerted measures, and oftentimes remains a
clinical challenge. Until recently, 5-year survival rates were
reported to be below 30% for patients with stage IVA/B disease
(Vokes et al, 1993) and 40% for all locally advanced tumours
(Laramore et al, 1992) even with early multimodality approaches
(30% recur locally, 25% distally).
PERSPECTIVE
Current management of locally advanced HNSCC (Table 1) has
evolved from poorly effective single modality therapy to an
integrated, highly effective multidisciplinary approach. Unlike
early stage HNSCC, all three modalities – surgery, radiotherapy,
and chemotherapy – play vital and complementary roles. The
various combination treatments have led to several competing
approaches, each with distinct advantages and disadvantages, and
initial treatment can vary significantly between institutions.
Therefore, the following paragraphs will examine each major
approach, highlight important differences and advantages/disad-
vantages, and attempt to recommend a management flowchart
based on the evidence. Treatments used for locally advanced
disease can be classified as follows:
i Surgery followed by adjuvant chemoradiotherapy (CRT) (or
radiation)
ii CRT upfront (with surgery as a salvage treatment)
iii Induction chemotherapy followed by definitive local therapy:
(a) CRT
(b)Other primary treatment options: radiotherapy, surgery
(7adjuvant therapy)
iv epidermal growth factor receptor (EGFR) inhibition in
combination with radiotherapy or CRT
Postoperative therapy: surgery followed by adjuvant CRT
(or radiation)
Predictors of recurrence after surgical resection include involved
margins of resection, extranodal/extracapsular spread, perineural
invasion, and the presence of two or more involved regional lymph
nodes (Snow et al, 1982; Vikram et al, 1984; Kramer et al, 1987).
Since locoregional failures remained the dominant problem,
adjuvant locoregional therapies such as radiation and subse-
quently CRT were added and adjuvant therapy is now considered
standard of care for stage III/IVA/B disease.
Adjuvant (postoperative) radiotherapy is well studied (Fletcher
and Evers 1970; Snow et al, 1982; Vikram et al, 1984; Kramer et al,
1987). It decreases local failure rates and although only retro-
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randomised prospective trial would be unrealistic at this point.
Still even with adjuvant radiotherapy, in the presence of high-risk
features, the risk of local recurrence (27–61%), distant metastases
(18–21%), and death (5-year survival rate 27–34%) remain
unsatisfactorily high (Cooper et al, 1998).
Postoperative (adjuvant) CRT offered an approach that could
enhance local control with radiosensitising chemotherapeutic
agents. Several studies have demonstrated that concurrent CRT
is a highly effective therapy for locally advanced HNSCC including
tumours that are not amenable to surgery (El-Sayed and Nelson
1996; Brizel et al, 1998; Vokes et al, 1999; Jeremic et al, 2000;
Adelstein et al, 2003; Vokes et al, 2003), justifying trials of
concurrent CRT as postoperative (adjuvant) treatment.
The first trial to suggest a marked benefit of postoperative CRT
over radiation alone in patients with locally advanced disease with
high-risk features was a smaller trial by Bachaud et al published in
1996 (Table 2a) (Bachaud et al, 1996). In order to confirm the
Bachaud trial, two similarly designed, multicentre, randomised
phase III trials of adjuvant radiation vs CRT were reported in 2004
(Bernier et al, 2004; Cooper et al, 2004) also in patients with stage
III, IVA/B disease and high-risk features for recurrence. The RTOG
9501 and the EORTC 22931 (summarised in Table 2) were able to
produce level 1 evidence of a clear benefit for adjuvant CRT, at the
cost of a significant increase in acute toxicities. Inclusion criteria
and the type of radiotherapy varied somewhat between the two
trials (Table 2), but overall they were coordinated to use similar
treatment protocols, making the results appear very robust. Both
trials support the benefit of CRT over radiation alone in patients
with high-risk features. Although only the EORTC trial showed a
significant survival advantage for CRT, the RTOG trial trended in
the same direction and showed a significant increase in progres-
sion-free survival.
Also consistent in both trials was an increase in acute grade III
and IV toxicities in the combined therapy arm (Table 2) including
toxic deaths. On the other hand, there was no difference in severe
long-term treatment-related toxicities. Strong consideration
should, therefore, be given to treatment of these patients in
centers with expertise in combined modality treatment and a well-
established supportive care system. A positive correlation of
treating institution expertise and patient survival supports this
belief (Benasso et al, 1997).
Although we can conclude that postoperative CRT in patients
with locally advanced disease with high-risk features is now
standard of care (Table 2a), for patients without high-risk features,
the evidence of a benefit of CRT over radiation alone is less clear
with no randomised trials addressing this question. The Inter-
group trial 0034 (Laramore et al, 1992) (see Table 2b) may give
some insight, but clearly was not intended to address this
particular question as it used sequential chemotherapy and
radiotherapy in comparison to radiation alone. This trial did
enroll a significant portion of intermediate risk patients (stage III
disease) without high-risk features and did not find a difference in
local control, disease-free, and overall survival. Interestingly, distal
failures were decreased presumably due to the higher doses of
systemic chemotherapy compared with concomitant CRT. Despite
the enrollment of lower risk patients, overall local control rates
were lower than in the more recent EORTC and RTOG trials. These
trials were reported 12 years apart and make comparisons difficult
due to stage migration and general improvements in supportive
care and therapeutic modalities.
Even though adjuvant concomitant CRT as reported in these two
landmark trials is a major step, it needs to be noted that the
locoregional failure rate remains unsatisfactorily high at 30%.
Attempts have been made to further improve the radiosensitising
properties of chemotherapy using doublet and triplet combina-
tions (see below) with the hope of further improving survival.
Many centres have adopted this approach, based on phase II
evidence indicating safety, feasibility, and potentially improved
efficacy, but this remains an unanswered question until phase III
data become available.
The optimal time frame to start adjuvant treatment postsurgery
has not been studied sufficiently. Limited evidence and clinical
experience with the time needed for patients to recover suggest
that it should be within 4–6 weeks postsurgery.
Definitive/concomitant CRT and organ preservation
During the past decade, an attractive alternative to initial surgery
has evolved. Originally pioneered for inoperable patients, upfront
concomitant CRT has emerged as a definitive treatment option
comparable to upfront surgical management in resectable patients.
Given its advantage with regards to organ preservation and
excellent reported local control and survival rates, CRT is
increasingly used and has become the dominant treatment
modality in many centres (Hoffman et al, 2004). The decision
between upfront surgery followed by chemoradiation vs upfront
chemoradiation with the option of salvage surgery remains
controversial and depends on many factors, including local
expertise, goals for organ preservation, operability, resectability,
and patient preference. No adequate randomised trial has
examined this question and, given inherent biases in patient
selection and ability to stage patients in a comparable fashion, it is
unlikely that we will have a definitive answer in the near future.
Both approaches work well, can coexist, and allow matching of
treatments to a patient’s disease and preferences.
Table 1 Staging overview, for details of T and N staging, please refer the AJCC staging manual
-Locally advanced disease stages discussed in this article are shaded in light grey. Oftentimes called intermediate stage disease in contrast to stage IVA/B disease, which carries a
higher risk of local recurrence. 5-Year survival, historically 1985–1991, rates vary depending on anatomic site of tumour; N/A¼not available. Used with the permission of the
American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for this material is the AJCC Cancer Staging Manual, Sixth Edition (2002) published by
Springer-Verlag New York, Inc.
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radiosensitising properties while delivering systemically active
agents. Sensitising effects though are not selective for tumour cells,
and adjacent normal tissue within the field is also subject to more
effective and more toxic radiation. Consistently, CRT trials report
an increased incidence of grade 3 and 4 acute toxicities with
mucositis and dermatitis being the most prominent. On the other
hand, severe long-term side effects are not increased in
comparison to radiation alone, and virtually all patients recover
from the intense treatment. As mentioned, treatment should
preferentially be done at experienced centres that have an
appropriate support infrastructure (Benasso et al, 1997).
Multiple phase II trials using intensive CRT regimens have
shown long-term survival rates of 60–70%, without surgery, for
locally advanced HNSCC (Kies et al, 2001; Adelstein et al, 2002;
Machtay et al, 2002; Vokes et al, 2003). Phase II trials need to be
interpreted with caution due to their inherent biases, but the
consistency of the results and the large number of patients treated
with this approach is reassuring. Meta-analysis of early rando-
mised, but mostly underpowered, trials suggested an absolute
survival benefit of approximately 8% at 5 years for CRT over
radiation also (NNT¼13; 13 patients need to be treated to save
one life) (El-Sayed and Nelson, 1996; Pignon et al, 2000). More
recent trials furthermore suggest even more robust survival
benefits with an absolute risk reduction of death at 3 years of
14–25% (NNT¼4–7; between 4 and 7 patients need to be treated
to save one life) (Brizel et al, 1998; Adelstein et al, 2003).
Based on suggestive phase II evidence, recent trials frequently
now investigate combination chemotherapy. Commonly used
agents include cisplatin, 5-FU (Table 2), taxanes, hydroxyurea,
and gemcitabine (Vokes et al, 2003; Milano et al, 2004).
Concomitant CRT is among the most efficacious locoregional
control measures, but at the same time, these recent trials reveal a
shift in the pattern of failure towards distant disease especially in
patients with advanced nodal stage. Induction chemotherapy
attempts to decrease distal failures has been advocated now that
local control is achieved in most patients (see below).
Even though some controversy remains, there is an increasingly
better defined role for surgical management of certain patients
after CRT (Argiris et al, 2004). Cervical lymph node dissection
(ND) even after a complete response (CR) to CRT is appropriate in
patients with N2-N3 disease to optimise locoregional disease
control (Lavertu et al, 1997; Argiris et al, 2004). Also, all patients
with residual lymph node enlargement on imaging should undergo
ND, even though many specimens will only show necrosis. In
patient with higher LN status (N2 and higher), up to 35% of
specimen will harbour residual microscopic tumour (Stenson et al,
2000). In a recent trial, this approach was able to improve
progression-free survival (Argiris et al, 2004). In contrast, patients
with N0-1 disease and a CR to treatment did not benefit. A selective
lymph node dissection is feasible 4–12 weeks after CRT and is
associated with an excellent safety profile (Stenson et al, 2000).
Organ preservation Given that concomitant CRT increases
locoregional control, and thereby avoids surgical resection of
important anatomical structures, it was postulated that CRT may
offer superior organ preservation in comparison to surgery,
radiation, or sequential chemotherapy and radiation. Initially,
Table 2a Postoperative therapy: randomised trials of adjuvant chemoradiotherapy vs radiotherapy alone in locally advanced HNSCC
Trial name Year
reported No of patients
Primary
treatment Adjuvant therapy
Toxicities – grades
3 and 4
Higher local
control rate
Survival difference
in favour of
ChemoRT
EORTC
a 22931
(Bernier et al, 2004)
167 with high-risk
features
Surgery ChemoRT (P)
RT
b
Acute: 41 vs 21%
Chronic: no difference
Yes 82 vs 69%
(at 5 years)
OS: Yes, HR¼0.7,
P¼0.02
DFS: Yes, HR¼0.75,
P¼0.04
RTOG
a 9501 (Cooper
et al, 2004)
459 with high-risk
features
Surgery ChemoRT (P)
RT
b
Acute: 77 vs 34%
Chronic: no difference
Yes 82 vs 72%
(at 2 years)
OS: No, HR¼0.84,
P¼0.19
DFS: Yes, HR¼0.78,
P¼0.04
Bachaud et al (1996) 83 with high-risk
features
Surgery ChemoRT (P)
RT
Acute: 41 vs 18%
Chronic: no difference
Yes 77 vs 59%
(at 4 years)
OS: Yes
DFS: Yes
EORTC¼European Organization for Research and Treatment of Cancer; RT¼radiotherapy; ChemoRT¼concurrent chemoradiotherapy; OS¼overall survival; DFS¼disease-
free survival; vs¼versus; HR¼hazard ratio; high-risk features¼please refer to paragraph on adjuvant, postoperative therapy.
aInclusion criteria at 4 years, not significant;
P¼Cisplatin. Inclusion criteria EORTC: The EORTC study defined four eligible groups of patients: (1) pathologically proven T3 or T4 primary tumours with any nodal stage (N),
except T3N0 completely resected laryngeal cancers (negative resection margins); (2) pT1 or pT2 tumours with an N2 or N3 nodal stage (M0); (3) patients with T1/T2 primary
tumours, N0/N1 nodal status but unfavourable pathological findings such as extranodal spread, positive resection margins, perineural involvement, or vascular tumor embolism;
(4) oral cavity or oropharyngeal tumours with involved lymph nodes at levels IV or V (lower jugular area and posterior neck triangle (Robbins et al, 1991). RTOG: any or all of the
following features needed to be present: (1) histologic evidence of invasion of two or more regional lymph nodes; (2) extracapsular spread of nodal disease; (3) microscopically
involved mucosal resection margins.
bRadiotherapy regimens EORTC: up to 54Gy in 27 fractions to a large volume including all tumour sites over a period of 5 1/2 weeks. High-risk
areas (risk for dissemination, inadequate resection margins) received a
[6]12-Gy boost (-total 66Gy; 33 fractions over a period of 6 1/2 weeks). RTOG: 60Gy in 30 fractions
over a 6-week period, with or without a boost of 6Gy in three fractions over a period of 3 days to high-risk sites.
Table 2b Postoperative therapy: randomised trial of adjuvant sequential chemotherapy+radiotherapy vs radiotherapy alone in locally advanced HNSCC
Trial name Year
reported No of patients
Primary
treatment Adjuvant therapy
Toxicities – grades
3 and 4
Higher Local
Control rate
Survival difference
in favour of
Chemo+RT
Intergroup 0034
(Laramore et al, 1992)
442 mix of
intermediate and high-
risk patients
Surgery Sequential Chemo
(PF)+RT
RT
Acute: no difference
Chronic: no difference
No 74 vs 71%
(at 4 years)
OS: No 48 vs 44%
a;
DFS: No 46 vs 38%
a
-Lower distal failure
rate; 15 vs 23%
(at 4 years)
RT¼radiotherapy; Chemo¼chemotherapy (cisplatin based); OS¼overall survival; DFS¼disease-free survival; vs¼versus; high-risk features¼please refer to paragraph on
adjuvant, postoperative therapy.
aAt 4 years, not significant; PF¼cisplatin + 5-FU.
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comparison to surgery with adjuvant radiation reported improved
organ preservation with no difference in survival (Table 3) (VA
Laryngeal cancer study group, 1991; Lefebvre et al, 1996, 2004),
establishing sequential treatment as a standard approach. At around
the same time, CRT emerged as a highly efficacious treatment and a
large Intergroup trial was therefore initiated. Intergroup trial 91–11
had as a primary end point larynx preservation in resectable
patients with stage III or IV (but excluding T4) disease (Table 3)
(Forastiere et al, 2003). The three treatment arms compared
sequential chemotherapy and radiation, concurrent CRT, and
radiotherapy alone. Laryngectomy was reserved for patients who
did not respond to induction chemotherapy or with residual or
recurrent disease following completion of radiotherapy on all three
arms. Laryngeal preservation, the primary end point of this trial,
was superior in the concomitant CRT arm compared to both
sequential CRT (88 vs 75% 2-year laryngeal preservation rate,
P¼0.005) and radiotherapy alone (88 vs 70% 2-year laryngeal
preservation, Po0.001). On the other hand, acute high-grade
toxicities were more common in both arms involving chemotherapy.
Similar to other CRT trials, late toxicities and swallowing function at
2 years were equivalent between the three arms. As a secondary
outcome, CRT achieved the highest locoregional control rate.
Survival was not significantly different between all three treatment
arms, while both chemotherapy arms showed lower distant failure
rates compared to radiotherapy alone. In conclusion concurrent
CRT should be considered standard of care in this patient
population. Sequential CRT is not more efficacious, but more toxic
than radiotherapy, and should therefore not be routinely used.
In other anatomical locations, no comparable level 1 evidence
for CRT exists. The earlier EORTC 24891 trial (Lefebvre et al, 1996,
2004) included hypopharynx tumours but only used sequential
CRT. Still, based on the superior locoregional control rates in
comparison to radiotherapy alone in locally advanced unresectable
patients, CRT is likely to be at the very least a reasonable choice for
organ preservation in general.
An evolving role for induction chemotherapy
The administration of induction chemotherapy prior to definitive
local therapy remains controversial. The interest in systemically
active chemotherapy arose from the observation that, with highly
effective local control measures, the majority of patients, who
failed therapy, would recur at a distant site. This was presumably
from micrometastatic disease that local therapy or lower dose
chemotherapy as part of chemoradiation would not adequately
treat. This theoretical argument has been tested in several trials
that have been unable to show a consistent survival benefit (1987;
Schuller et al, 1988; 1991; Paccagnella et al, 1994; El-Sayed and
Nelson 1996; Domenge et al, 2000; Pignon et al, 2000). (Table 4a).
Design issues as well as concerns that less effective local therapy in
the past may have decreased the power to show a survival benefit,
remain. Nevertheless, induction chemotherapy continues to be an
ongoing area of research with several centres around the world
continuing to investigate this approach, which can produce CR
rates in 30–65% of patients and overall response rates of 70–85%
(Hitt et al, 2003; Knecht et al, 2003; Knecht et al, 2003; Gustin et al,
2004; Nadeem et al, 2004; Vermorken et al, 2004).
Two European studies have shown evidence of a survival benefit
with induction chemotherapy: the Italian GSTTC study (Gruppo di
Studio sui Tumori della Testa) (Domenge et al, 2000) demon-
strated increased cure rates in a subset of nonoperable patients and
the French GETTEC trial (Groupe d’Etude des Tumeurs de la Tete
et du Cou), which was closed early (Paccagnella et al, 1994). A
large meta-analysis by Pignon et al (2000) furthermore showed a
5% increase in survival only for trials using a cisplatin/fluorouracil
(5-FU) combination, reaching statistical significance (P¼0.05).
More recently, two trials compared a triplet combination of a
taxane (docetaxel or paclitaxel), cisplatin, and 5-FU (TPF) with
doublet cisplatin/5-FU (PF) (Hitt et al, 2003; Vermorken et al,
2004). Consistent in both randomised trials, TPF was well tolerated
and significantly more effective in particular in the recently
reported EORTC 24971 trial by Vermorken et al (2004), where a
significant difference in overall survival was seen. The trials are not
fully published, but the data from both trials are consistent
suggesting that a triplet combination (TPF) including a taxane has
potential to emerge as a standard choice for induction chemo-
therapy in the future.
Still induction chemotherapy cannot be considered standard of
care due to the lack of convincing phase III evidence, but lower
level evidence suggests that it is reasonably safe and may benefit
patients at high risk for distal failure as indicated by advanced
nodal involvement. The triplet combination of a taxane, cisplatin,
and 5-FU seems to have a high degree of activity and acceptable
toxicity (Table 4b) (Hitt et al, 2003; Knecht et al, 2003; Vermorken
et al, 2004).
Induction chemotherapy and concomitant CRT The combination
of induction chemotherapy and concomitant CRT appears to be of
particular interest due to their complementary effects with the
Table 3 Chemoradiotherapy vs other modalities for organ preservation in locally advanced HNSCC
P¼cisplatin; F¼5-fluorouracil; RT¼radiotherapy; *¼statistically significant P¼0.005 and Po0.001 in pairwise comparison. Surgery as local salvage therapy. No difference
chronic tox.; NA¼not available; HR¼hazard ratio. Shaded area: Organ Preservation Trials that do not include current standard of care of chemoradiotherapy, but lead to the
more definitive intergroup trial.
State-of-the-art management of HNSCC
TY Seiwert and EEW Cohen
1344
British Journal of Cancer (2005) 92(8), 1341–1348 & 2005 Cancer Research UKformer leading to a reduction of distant disease and the latter
achieving locoregional control. Results of induction chemotherapy
followed by CRT are encouraging (Hainsworth et al, 2002; Machtay
et al, 2002; Haraf et al, 2003; Vokes et al, 2003) (Table 4b) and
suggest a reasonable toxicity profile, lower distal failure rates, and
improved survival in comparison with historical controls using the
same CRT regimen (Vokes et al, 2003).
In summary, there is a possibility that induction chemotherapy
may improve survival in locally advanced HNSCC in combination
with CRT as suggested by lower level evidence. Adequate phase III
evidence is not available currently, and until further data become
available, induction chemotherapy should not be used routinely in
HNSCC outside a clinical trial, but may be appropriate given its
well-established safety profile in high-risk situations.
Epidermal growth factor receptor inhibition in
combination with radiotherapy or CRT
The EGF receptor as well as its principal ligand TGF-a are
expressed in approximately 80% of HNSCC (Grandis et al, 1996;
Grandis et al, 1998) and play an important role in the biology of
this disease (Barrandon and Green 1987; Grandis et al, 1998; O-
charoenrat et al, 2000; Veikkola et al, 2000; Ang et al, 2002). A
multitude of agents inhibiting EGFR are in various stages of
development and encouraging single agent activity has been
reported in recurrent or metastatic HNSCC (Cohen EE et al, 2003;
Soulieres et al, 2004). Despite the high efficacy of current
treatments, EGFR inhibitors hold promise in two important ways:
(1) to further improve efficacy for patients at risk for recurrence
and (2) to decrease treatment-related toxicities by replacing more
toxic cytotoxic drugs without jeopardising survival.
A phase III multicentre trial (Bonner et al, 2004) enrolled 424
patients with stage III/IV HNSCC randomising them to receive
radiotherapy with or without concomitant cetuximab, a humanised
monoclonal antibody directed against the EGFR, as a primary
treatment. Overall, the regimen was well tolerated, with an increase in
grade 3 cutaneous toxicity from 18 to 34% and some mild increases
in allergic reactions. Even though only preliminary data are available,
a marked increase in median overall survival from 28 months with
radiation alone to 54 months with the addition of cetuximab was
reported. Locoregional control was significantly improved in the
cetuximab arm as well (48 vs 56% at 2 years, P¼0.02).
These reports are very encouraging; however, the major
difficulty in interpreting and using these data is that it remains
unclear how radiotherapy plus cetuximab compares to CRT as the
reported trial used a control arm that would be considered inferior
in light of recent evidence discussed above. Given the immature
nature of the data and in particular the inability to compare to
current standards of care, it is prudent to wait until further
information becomes available. Still it is reasonable to consider
this regimen in patients with poor performance status, who are not
good candidates for CRT or surgery.
Another report of the combination of gefitinib with CRT (5-FU,
hydroxyurea, and twice daily radiotherapy), following induction
chemotherapy and followed by gefitinib maintenance, provided
insights into a potential role for EGFR inhibitors (Cohen EW et al,
2004). In comparison to previous similarly designed trials, this
treatment was at least as efficacious as a comparable taxane-
containing regimen (paclitaxel, 5-FU, hydroxyurea, and radio-
therapy) (Vokes et al, 1999) and better tolerated. Another trial
exploring the combination of gefitinib and radiation with or without
cisplatin is currently ongoing and demonstrates that the combina-
tion of gefitinib with cisplatin and radiotherapy appears feasible.
CONCLUSION
Treatment for locally advanced HNSCC has improved dramatically
during the past decade, allowing a discussion of cure in many
patients, and an evidence-based algorithm to guide treatment can
be created (Figure 1). In particular, CRT has established itself as a
central treatment modality either upfront as definitive therapy or
as an adjuvant to surgery, due to its excellent local control rates,
increased survival, and higher rates of organ preservation. For the
future, the integration of EGFR inhibitors is poised to play an
increasingly important curative role while potentially decreasing
Table 4a Randomized trials of induction (Neoadjuvant) chemotherapy vs no induction chemotherapy in locally advanced HNSCC
Trial N Induction chemotherapy Local therapy Survival difference Lower distant failure
HNCP (Head & Neck Contracts Program, 1987) 462 PB X 1
P BX1 ,PX6
a
None
S, RT
S, RT
S, RT
No Yes, arm B
SWOG (Schuller et al, 1988) 158 PMBV X 3
None
S, RT
S, RT
No No, P¼0.07
GSTTC (Paccagnella et al, 1994) 237 PF X 4
None
S, RT
b
S, RT
Yes, for inoperable patients only Yes
GETTEC (Domenge et al, 2000) 318 PF X 3
None
S, RT
b
S, RT
Yes No
HNCP¼head and neck contracts program; SWOG¼southwest oncology group; GSTTC¼Gruppo di Studio sui Tumori della Testa e del Collo; GETTEC¼Groupe d’Etude
des Tumeurs do la Tete et du Cou; RT¼radiotherapy; S¼surgery; P¼cisplatin; F¼5-fluorouracil; B¼bleomycin; M¼methotrexate; V¼vincristine; N/A¼not applicable.
aArm B of the HNCP trial administered one cycle of induction and six cycles of adjuvant chemotherapy.
bPatients on the GSTTC and GETTEC studies received local therapy
based on operability: operable patients received surgery and adjuvant RT; inoperable patients received 65–70Gy RT.
Table 4b Randomized trials of comparing PF vs TPF induction (neoadjuvant) chemotherapies
Trial N Chemotherapy Local Therapy Survival Difference Toxic deaths
Hitt et al (2003) 383 PF X 3
TPF X 3
(T¼paclitaxel)
CRT (P)
CRT (P)
Yes, HR¼0.79 in favour of TPF; P¼0.038 PF: 4.1%
TPF: 2.1%
NS
EORTC 24971
(Vermorken et al, 2004)
358 PF X 4
TPF X 4
(T¼docetaxel)
RT
RT
Yes, HR¼0.73 in favor of TPF; P¼0.016 PF: 5.5%
TPF: 2.3%
Significant
EORTC¼European Organization for Research and Treatment of Cancer; CRT¼chemoradiotherapy; RT¼surgery; P¼cisplatin; F¼5-fluorouracil; T¼taxane; N/A¼not
applicable; NS¼not significant; HR¼hazard ratio.
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Cisplatin − single agent 
(30% local failure rate) 
Level I evidence 
Combination chemo 
(P/5-FU, TFHX − lower
local failure rate) 
Level III evidence
Good  Poor 
Resectable? 
No Yes 
Locally advanced
HNSCC
Stages III, IVA/B 
Careful evaluation of 
treatment goals 
→  Organ preservation? 
→  Performance status? 
→  Patient preferences? 
Performance status? 
Chemoradiotherapy∗∗∗
Level I evidence 
Pathology review 
High-risk features?∗ 
Yes No 
Surgery 
Level I evidence 
Staging
(CT H/N, chest, ENT exam
+/− additional studies)
Consider induction 
chemotherapy to 
decrease risk of distant 
failure  
Level III evidence 
Consider induction chemotherapy to 
decrease risk of distant failure  
Level III evidence 
Radiation with 
concomitant 
cetuximab∗∗ 
Level II evidence∗∗ 
Chemoradiotherapy 
at reduced intensity 
Expert opinion
Radiation 
Palliative measures
Radiation 
vs no treatment: 
Level II evidence 
vs chemoradiation: 
Expert opinion
• •
•
•
Figure 1 Evidence-based treatment algorithm for management of locally advanced HNSCC.
Levels of evidence supporting recommendation:
Level 1: Multiple consistent phase III studies, or one large, high-quality multicentre phase III trial
Level 2: Smaller, single-phase III trial
Level 3: Multiple consistent phase II studies
Level 4: Expert opinion or evidence less than level 3
*High-risk features for recurrence are:
K Involved margins of resection
K Extranodal/extracapsular spread
K Perineural invasion
K Presence of two or more involved regional lymph nodes
**At the time of publication, emerging Level 2 evidence in comparison to radiotherapy single modality. No data are available in comparison to chemoradiotherapy (CRT),
therefore no recommendation can be made in comparison to CRT; the authors therefore recommend this treatment option only for patients with a low performance
status, who are poor candidates for chemoradiotherapy.
***Referral to experienced centre with adequate support system recommended.
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current knowledge and abilities and enforce quality standards to
allow as many patients as possible to benefit from already excellent
treatment approaches.
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